Accedi ai contenuti
Registrati »
Accedi ai contenuti
Registrati »
HomeLetteratura
Archivio

The Oncology Pharmacy Team (OPT), consisting of specialty-trained pharmacists and/or pharmacy technicians, is an integral component of the multidisciplinary healthcare team (MHT) involved with all aspects of cancer patient care. The OPT fosters quality patient care, safety, and local regulatory compliance. The International Society of Oncology Pharmacy Practitioners (ISOPP) developed this

Oncology Pharmacy Practice 2021;27(4):785-801. /  Holle LM, Bilse T, Alabelewe RM, et al.

Background: Beta thalassemia patients, post-bone marrow transplant, and leukemia patients require long term therapy with an intense care follow-up especially for pediatric hematology–oncology origin. Emergence of side effects and noncompliance to therapy lead to reduced efficacy of medicines resulting in relapse of diseases. There is an increasing fact to support

Journal of Oncology Pharmacy Practice 2021;27(4):815-820. /  Ali K, Al-Quteimat O, Naseem R, et al.

The use of high-dose intravenous immune globulin (IVIG) plus anticoagulation is recommended for the treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare side effect of adenoviral vector vaccines against coronavirus disease 2019 (Covid-19). We describe the response to IVIG therapy in three of the first patients in whom VITT

N Engl J Med. 2021 Jun 9 Epub ahead of print] /  Bourguignon A, Arnold DM, Warkentin TE, Smith JW, Pannu T,

Background: Multiple factors have defined the success of treatment with oral antineoplastic, especially adherence to the therapeutic regimen. The aim of this study was to describe the profile of individuals in treatment with oral antineoplastic according to the sociodemographic and clinical epidemiology factors as well as to estimate

J Oncol Pharm Pract 2021 may 29 [Online ahead of print] /  Silva TB, et al.

Objectives: To assess the prevalence of and factors associated with Post-Coronavirus Disease 2019 (COVID-19) syndrome six months after the onset. Methods: A bidirectional prospective study. Interviews investigated symptoms potentially associated with COVID-19 six months after the disease onset of all consecutive adult in- and out-patients with COVID-19 attending

Clin Microbiol Infect 2021:S1198-743X(21)00281. /  Peghin M, Palese A, Venturini M, et al.

Background: Most pts with r/r FL experience multiple relapses and progressively worse clinical outcomes with each line of therapy, underlining a need for novel therapies. Tisa-cel has demonstrated durable responses and manageable safety in adult pts with r/r diffuse large B-cell lymphoma. Here we report the primary analysis of ELARA,

J Clin Oncol 39 2021; suppl15 abstr 7508. /  Schuster SJ, et al.

Background: The Phase III MONALEESA-3 trial (NCT02422615) previously demonstrated a statistically significant improvement in OS with RIB, a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), plus FUL compared with placebo (PBO) plus FUL as first-line (1L) or second-line (2L) treatment in postmenopausal pts with HR+/HER2− ABC (median, not reached vs 40.0 mo;

J Clin Oncol 39, 2021 (suppl 15; abstr 1001). /  Slamon Dj, et al.

Background: Historically, the long-term prognosis has been poor in patients (pts) with acute graft-vs-host disease (aGVHD) who fail initial treatment with steroids. REACH2 (NCT02913261; N=309) is a randomized, phase 3 trial investigating the efficacy and safety of the Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib (RUX) vs best available therapy (BAT)

EHA Virtual Meeting 2021; abstract #S236. /  Szer J, et al.

Governments and health insurers often make funding decisions based on health gains from randomised controlled trials. These decisions are inherently uncertain because health gains in trials may not translate to practice owing to differences in the population, treatment use and setting. Post-market analysis of real-world data can provide additional evidence but

Pharmacoeconomics 2021 Apr 9 [Epub ahead of print] /  Ghijben P, Petrie D, Zavarsek S, et al.

There is growing interest in using observational data to assess the safety, effectiveness, and cost effectiveness of medical technologies, but operational, technical, and methodological challenges limit its more widespread use. Common data models and federated data networks offer a potential solution to many of these problems. The open-source Observational and Medical

PharmacoEconomics 2021; 39: 275–285. /  Kent S, Burn E, Dawoud D, et al.